P2.01-01 Cemiplimab, a Human PD-1 Monoclonal Antibody, Versus Chemotherapy in First-Line Treatment of Advanced NSCLC with PD-L1 ≥50%
Year: 2019
Type: article
Source: Journal of Thoracic Oncology
Authors: A. Sezer, M. Gogishvili, D. Bentsion, S. Kilickap, A. Lowczak, M. Gumus, O. Gladkov, P. Clingan, V. Sriuranpong, N. Rizvi, S. Lee, S. Li, P. Snodgrass, M. Navarro, I. Lowy, P. Rietschel
Institutions: Başkent University, Hacettepe University, University of Warmia and Mazury in Olsztyn, Istanbul Medeniyet University, Chelyabinsk Regional Clinical Oncology Center, University of Wollongong, Wollongong Hospital, Illawarra Health and Medical Research Institute, Chulalongkorn University, King Chulalongkorn Memorial Hospital, Columbia University Irving Medical Center, Regeneron (United States)
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W2982093402